



HUNTINGTON MEDICAL RESEARCH INSTITUTES

BOARD OF DIRECTORS

ROGER ENGEMANN
President
MICHAEL C. DOYLE
Vice President
JOHN W. RUSSELL
Secretary
HAROLD J. MEYERMAN
Treasurer
WILLIAM OPEL, Ph.D.
Executive Director
JOHN D. BALDESCHWIELER, Ph.D.
RICHARD J. BING, M.D.
DANIEL M. BRIGHAM, JR.
WILLIAM G. COREY, M.D.
ANN SLAVIK HALL
JERRY M. HARRINGTON
HERBERT HEZLEP III
THOMAS E. HIGGINS
MITCHELL B. HOWE, JR.
R. WILLIAM JOHNSTON
LAWRENCE W. JONES, M.D.
NELSON D. JONES
C. L. KEEDY
WILLIAM G. KING III
ROBERT J. MACKIN, JR., Ph.D.
ROBERT D. MAY
LYNN H. MYERS
JOHN H. RICHARDS, Ph.D.
PHILIP V. SWAN
ROBERT E. TRANQUADA, M.D.

www.hmri.org

ADMINISTRATIVE OFFICES
(626) 397-5801 FAX: (626) 397-5808
NEURAL ENGINEERING
(626) 397-5850 FAX: (626) 397-5857
734 Fairmount Avenue
Pasadena, CA 91105-3104

BUSINESS OFFICE
CELL THERAPY LABORATORIES
PROSTATE RESEARCH PROGRAM
(626) 795-4343 FAX: (626) 795-5774
CARDIOLOGY LABORATORY
(626) 397-5860 FAX: (626) 795-5774
99 North El Molino Avenue
Pasadena, CA 91101-1830

CANCER GENETICS LABORATORY
MOLECULAR NEUROLOGY LABORATORY
635 East Union Street
Pasadena, CA 91101-1719
(626) 795-4343 FAX: (626) 795-5774

LIVER CENTER
660 South Fair Oaks Avenue
Pasadena, CA 91105
(626) 397-5820 FAX: (626) 397-5827

MAGNETIC RESONANCE
IMAGING CENTER
(626) 397-5881 FAX: (626) 397-5889
MEG BRAIN MAPPING CENTER
(626) 796-7874 FAX: (626) 796-6875
NEUROSURGICAL RESEARCH
PROGRAM
(626) 397-5831 FAX: (626) 397-5846
10 Pico Street
Pasadena, CA 91105-3201

MAGNETIC RESONANCE
SPECTROSCOPY LABORATORY
(626) 397-5840 FAX: (626) 397-5846
660 South Fair Oaks Avenue
Pasadena, CA 91105-2616

November 2, 2007

Kevin J. Martin
Chairman
Federal Communications Commission
445 12th Street, SW
Washington, D.C. 20554

Re: Alfred Mann Foundation Petition for Rulemaking
RM-11404


Dear Chairman Martin:

I am writing to express my enthusiastic support for the Alfred Mann Foundation's ("AMF") request for a rulemaking to facilitate deployment of new wideband medical micropower network service ("MMNS") devices that will dramatically improve the lives of patients suffering from Parkinson's Disease (PD) and similar movement disorders that are amenable to treatment by deep brain stimulation. As a scientist and biomedical engineer specializing in the development of neural implants for functional electrical stimulation (FES) including advanced devices for deep brain stimulation, I have first-hand knowledge of the severe impact that PD has upon the physical and emotional well-being of patients and their families. In particular, wide-band communication between an external computer and the implant pulse generator will be essential for development of the next generation of adaptive deep-brain stimulation systems that can record neuronal activity from many sites within the target nucleus (e.g., the subthalamic nucleus) and direct titrated electrical stimulation into only the appropriate part of the target so as to suppress the abnormal neuronal activity. I am well aware of the limitations of the available medical treatment options and of the currently unfulfilled need for wireless, implantable miniature devices that can rehabilitate paralyzed limbs and organs, which is the objective of the advance neuromuscular stimulation systems that AMF is developing.

Kevin J. Martin, Chairman
November 2, 2007
Page 2

In response to the Commission's notice of inquiry in ET Docket No. 06-135, I previously filed comments supporting AMF's request for a rulemaking and reiterate that support here. I firmly believe that the MMNS equipment that AMF is developing represents a quantum leap in FESS technology and that it and related device that will require wide-band wireless communication with implanted pulse generators will provide great benefits to people living with prevalent movement disorders including advanced Parkinson's Disease. These persons certainly will receive greater benefit from more advanced, adaptive DBS systems that operate in a closed-loop mode. In view of the significant health benefits, the Commission should adopt rules facilitating the development and deployment of new and innovative MMNS equipment. Moreover, because of the length of time required to complete the regulatory process, it is critical that the Commission commence the necessary rulemaking proceeding as soon as possible. The sooner the Commission can initiate the process the sooner patients can begin to realize the extraordinary benefits of this groundbreaking technology.

Sincerely,



Douglas B McCreery, PhD
Director, Neural Engineering Program
Huntington Medical Research Institutes

cc: Marlene H. Dortch
FCC Secretary

CERTIFICATE OF SERVICE

I hereby certify that on November 2, 2007, a copy of the foregoing Letter was served by electronic mail upon the following:

Cheryl A. Tritt
Morrison & Foerster LLP
2000 Pennsylvania Avenue, NW
Washington, DC 20006

Email: CTritt@mofo.com

Counsel to the Alfred Mann Foundation

/s/ Douglas B. McCreery, PhD
Douglas B. McCreery, PhD